The Role of ctDNA Testing Plus AI-based Pathology in Resectable LSCC

Summary

The goal of this observational study is to explore whether ctDNA dynamic monitoring plus AI-based pathology can more effectively predict the therapeutic effect of neoadjuvant chemoimmunotherapy for resectable lung squamous cell carcinoma, so as to accurately guide clinical diagnosis and treatment.

Eligibility

Inclusion Criteria:

* Histopathology or cytology confirmed the lung squamous cell carcinoma
* Age ranging from 18 to 75
* Agree to participate in this study and sign an informed consent form
* Treatment-naive tumor
* According to the American Joint Committee on Cancer (AJCC) eighth edition of the Lung Cancer Staging Manual, the clinical stage is stage II-IIIb resectable or potentially resectable tumor
* Sufficient tissue/blood samples are available to meet research requirements
* The ECOG PS score is 0-1

Exclusion Criteria:

* Patients who cannot understand the content of the experiment and cannot cooperate, and those who refuse to sign the informed consent form
* Non-squamous NSCLC
* Unresectable IIIa-IIIb tumor
* Patients with solid organ or blood system transplantation
* Previous use of CTLA-4, PD-1, or PD-L1 immune checkpoint inhibitors
* Patients with interstitial lung disease
* Patients with acute or chronic infectious disease
* Pregnant and lactating women
* Patients who have undergone other clinical drug trials

Conditions3

Browse More Trials